Boron in drug design: Recent advances in the development of new therapeutic agents

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (Unesp)-
Autor(es): dc.contributorUniv Auckland-
Autor(es): dc.creatorSantos Fernandes, Guilherme Felipe [UNESP]-
Autor(es): dc.creatorDenny, William Alexander-
Autor(es): dc.creatorDos Santos, Jean Leandro [UNESP]-
Data de aceite: dc.date.accessioned2022-02-22T00:04:05Z-
Data de disponibilização: dc.date.available2022-02-22T00:04:05Z-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2020-12-09-
Data de envio: dc.date.issued2019-10-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.ejmech.2019.06.092-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/194847-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/194847-
Descrição: dc.descriptionAdvances in the field of boron chemistry have expanded the application of this element in Medicinal Chemistry. Boron-containing compounds represent a new class for medicinal chemists to use in their drug designs. Bortezomib (Velcade (R)), a dipeptide boronic acid approved by the FDA in 2003 for treatment of multiple myeloma, paved the way for the discovery of new boron-containing compounds. After its approval, two other boron-containing compounds have been approved, tavaborole (Kerydin (R)) for the treatment of onychomicosis and crisaborole (Eucrisa (R)) for the treatment of mild to moderate atopic dermatitis. A number of boron-containing compounds have been described and evaluated for a plethora of therapeutic applications. The present review is intended to highlight the recent advances related to boron-containing compounds and their therapeutic applications. Here, we focused only in those most biologically active compounds with proven in vitro and/or in vivo efficacy in the therapeutic area published in the last years. (C) 2019 Elsevier Masson SAS. All rights reserved.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionPrograma de Apoio ao Desenvolvimento Cientifico da Faculdade de Ciencias Farmaceuticas da UNESP-PADC-
Descrição: dc.descriptionSao Paulo State Univ, Sch Pharmaceut Sci, BR-14800903 Araraquara, Brazil-
Descrição: dc.descriptionSao Paulo State Univ, Inst Chem, BR-14800060 Araraquara, Brazil-
Descrição: dc.descriptionUniv Auckland, Fac Med & Hlth Sci, Auckland Canc Soc Res Ctr, Auckland, New Zealand-
Descrição: dc.descriptionSao Paulo State Univ, Sch Pharmaceut Sci, BR-14800903 Araraquara, Brazil-
Descrição: dc.descriptionSao Paulo State Univ, Inst Chem, BR-14800060 Araraquara, Brazil-
Descrição: dc.descriptionFAPESP: 2016/09502-7-
Descrição: dc.descriptionFAPESP: 2018/17739-2-
Descrição: dc.descriptionFAPESP: 2018/11079-0-
Formato: dc.format791-804-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier B.V.-
Relação: dc.relationEuropean Journal Of Medicinal Chemistry-
???dc.source???: dc.sourceWeb of Science-
Palavras-chave: dc.subjectBoron-
Palavras-chave: dc.subjectDrug design-
Palavras-chave: dc.subjectBoron-containing compounds-
Palavras-chave: dc.subjectBiological activity-
Palavras-chave: dc.subjectBoronic acids-
Palavras-chave: dc.subjectBenzoxaboroles-
Título: dc.titleBoron in drug design: Recent advances in the development of new therapeutic agents-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.